PriceTargets.com logo

Catalyst Biosciences - CBIO Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 10/31/2023 12:59 AM ET
+0 (0.00%)
Get New Catalyst Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CBIO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CBIO

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Catalyst Biosciences in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for CBIO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Catalyst Biosciences. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/24/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/22/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/22/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/21/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/19/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/17/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/17/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/16/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/12/2021JonestradingDowngradeBuy ➝ HoldHigh
11/12/2021Piper SandlerLower TargetOverweight$16.00 ➝ $4.00High
11/12/2021Raymond JamesDowngradeOutperform ➝ Market PerformHigh
9/10/2021JonestradingReiterated RatingBuy$18.00Medium
8/9/2021JonestradingInitiated CoverageBuy$18.00Low
8/6/2021Raymond JamesLower TargetOutperform$19.00 ➝ $18.00Medium
7/20/2021Raymond JamesSet TargetBuy$4.31High
7/1/2021Chardan CapitalReiterated RatingBuyHigh
4/29/2021Raymond JamesBoost TargetOutperform$18.00 ➝ $19.00Low
3/4/2021Raymond JamesSet TargetOutperform$18.00High
2/10/2021Piper SandlerInitiated CoverageOverweight$15.00Low
2/4/2021Raymond JamesLower TargetOutperform$20.00 ➝ $18.00High
12/15/2020Raymond JamesSet TargetOutperform$20.00Medium
12/3/2020Raymond JamesReiterated RatingOutperform$20.00High
11/5/2020Lifesci CapitalReiterated RatingOutperformHigh
11/5/2020Raymond JamesReiterated RatingBuy$20.00High
8/7/2020Raymond JamesSet TargetOutperform$20.00N/A
8/6/2020Ci CapitalReiterated RatingBuy$18.00Low
7/22/2020Ci CapitalReiterated RatingBuy$19.00Low
7/14/2020Raymond JamesSet TargetOutperform$20.00Low
6/17/2020Raymond JamesSet TargetOutperform$20.00High
6/11/2020Raymond JamesSet TargetOutperform$20.00Low
5/21/2020Raymond JamesInitiated CoverageOutperform$20.00High
12/19/2019Chardan CapitalReiterated RatingBuy$25.00High
11/10/2019Chardan CapitalReiterated RatingBuy$25.00Low
8/25/2019Chardan CapitalSet TargetBuy$25.00High
(Data available from 4/16/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/19/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/17/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/16/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/17/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/16/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Catalyst Biosciences logo
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.77
Low: $0.34
High: $7.67

52 Week Range

Now: N/A

Volume

32,246 shs

Average Volume

763,526 shs

Market Capitalization

$291.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.05

Frequently Asked Questions

What sell-side analysts currently cover shares of Catalyst Biosciences?

The following Wall Street research analysts have issued research reports on Catalyst Biosciences in the last year:
View the latest analyst ratings for CBIO.

What is the current price target for Catalyst Biosciences?

0 Wall Street analysts have set twelve-month price targets for Catalyst Biosciences in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Catalyst Biosciences in the next year.
View the latest price targets for CBIO.

What is the current consensus analyst rating for Catalyst Biosciences?

Catalyst Biosciences currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CBIO.

What other companies compete with Catalyst Biosciences?

Other companies that are similar to Catalyst Biosciences include XOMA, Verastem, Vanda Pharmaceuticals, Rigel Pharmaceuticals and Merrimack Pharmaceuticals. Learn More about companies similar to Catalyst Biosciences.

How do I contact Catalyst Biosciences' investor relations team?

Catalyst Biosciences' physical mailing address is 611 GATEWAY BLVD. SUITE 710, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company's listed phone number is (650) 871-0761 and its investor relations email address is [email protected]. The official website for Catalyst Biosciences is www.catalystbiosciences.com. Learn More about contacing Catalyst Biosciences investor relations.